Shares of CalciMedica shifted sharply higher Monday, trading at $1.07 — up 8.8% — as the market continued to digest a July 3 regulatory filing revealing that Bering Partners II, L.P. quietly built a 6.9% ownership stake through a private placement completed June 25. The move comes against a backdrop of broader market weakness, making the micro-cap biotech's rally all the more conspicuous. A Venture Fund Paid 80 Cents a Share for CalciMedica — So Why Is the Stock Now Worth $1.07, and Can It Last?
Shares of CalciMedica jumped 8.8% to $1.07 Monday, defying a weaker broad market, as traders continued to parse a Schedule 13D filing showing venture fund Bering Partners II quietly accumulated a 6.9% stake — roughly 2.1 million shares — in the pre-revenue biotech. The position was built through a combination of merger consideration, prior private placements, open-market purchases, and a June 25 private placement in which Bering II bought 1,450,267 units at $0.8033 per unit. No new company-specific catalyst has emerged today.
A Well-Connected Buyer Paid a Steep Discount
Bering II paid roughly $1.16 million for its June 25 tranche at just $0.80 per unit. That price sits 25% below today's quote, giving the fund an immediate paper gain. More notable: a managing member of Bering's general partner sits on CalciMedica's board , suggesting insider-level conviction — but also raising the question of whether this is genuine strategic interest or simply a discounted deal for a connected party.
The Filing Switched From Passive to Active — and That Matters
Bering upgraded its disclosure from a 13G (passive holder) to a 13D, which signals the right to influence management, and raised its warrant ownership cap to 19.99%. In plain terms, this investor is reserving the option to nearly triple its voting power, which could reshape governance at a company with only about 30.7 million shares outstanding.
The Company Is Burning Cash With No Revenue
CalciMedica posted operating income of -$23.1 million and operating cash flow of -$21.2 million in the trailing twelve months, with zero product sales. A June 24 private placement for up to ~$49 million is designed to fund a pulmonary hypertension trial program , but upfront proceeds total only about $15 million , extending the runway merely into the second half of 2027. Its lead kidney-injury trial was halted in January on safety concerns , though the FDA later cleared the drug to continue development after reviewing interim safety data .
A $33 Million Company With a Long Road Ahead At $1.07, CalciMedica's market cap is roughly $33 million on a post-placement share count. The stock has traded between $0.46 and $7.20 over the past year , underscoring extreme volatility. Bering's stake adds a credible backer, but the next real inflection point — FDA feedback on a pivotal acute-pancreatitis trial design, expected in Q3 2026 — remains months away. Until then, investors are trading on faith, not fundamentals.